miRNA Plasmid Composition for Coagulation Factor Downregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulation of bioactive molecules, such as coagulation factors, leads to homeostasis disruption and associated diseases, necessitating therapies to regulate their expression.
Innovation Solution
Compositions comprising recombinant plasmids that encode miRNA sequences targeting and degrading mRNA of coagulation factors, like factor X, to upregulate miRNA production and reduce biomolecule availability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If coagulation factors are over-expressed to enhance hemostatic function, then bleeding control improves, but homeostasis is disrupted and thrombotic disease risk increases
Solution Approach 1:
The patent employs feedback control by designing miRNA compositions that respond to elevated coagulation factor levels. When factor X or other coagulation factors are over-expressed, the miRNA compositions are administered to specifically degrade the corresponding mRNA, thereby reducing the bioactive molecule levels back toward homeostasis and preventing thrombotic complications.
Solution Approach 2:
The patent changes the regulatory parameters of coagulation factor expression by introducing miRNA that targets specific mRNA sequences. This allows dynamic modulation of protein levels - the miRNA can be tuned to achieve desired expression levels that maintain hemostatic reliability while avoiding pathological thrombosis.
2Object-affected harmful factors
If miRNA compositions are administered to downregulate coagulation factors, then thrombotic risk decreases, but hemostatic protection may be compromised
Solution Approach 1:
The patent applies local quality by using highly specific miRNA sequences that target only particular coagulation factor mRNAs (e.g., factor X, factor IX, or factor VIII specifically). This specificity ensures that only the intended coagulation pathway components are downregulated, preserving other essential hemostatic functions and avoiding broad suppression that would compromise overall hemostatic protection.
Solution Approach 2:
The patent employs partial action by administering miRNA compositions at controlled doses that achieve sufficient downregulation of pathological coagulation factors to reduce thrombotic risk, while maintaining enough residual activity to preserve essential hemostatic protection. The dosage and specificity are tuned to achieve the optimal partial effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively downregulate coagulation factor expression by enhancing endogenous miRNA production, thereby ameliorating dysregulated biomolecule levels and preventing or treating associated diseases.
Implementation Method 1
the sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated
Implementation Method 2
the compositions comprise a plasmid of deoxyribonucleic acid (DNA) that includes one or more insert sequences of nucleotides that encode for the production of miRNA and a backbone sequence of nucleic acids that facilitates introduction of the one or more insert sequences into one or more of a subject's cells where it is expressed and/or replicated
Data Source
AI summary
The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as factor X. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.